{"id":246974,"date":"2026-11-09T22:14:37","date_gmt":"2026-11-10T04:14:37","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/11\/retatrutide-reduces-knee-osteoarthritis-pain-and-weight-improves-physical-function"},"modified":"2026-11-09T22:14:37","modified_gmt":"2026-11-10T04:14:37","slug":"retatrutide-reduces-knee-osteoarthritis-pain-and-weight-improves-physical-function","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/11\/retatrutide-reduces-knee-osteoarthritis-pain-and-weight-improves-physical-function","title":{"rendered":"Retatrutide Reduces Knee Osteoarthritis Pain and Weight, Improves Physical Function"},"content":{"rendered":"\n<p>The investigational triple incretin agonist drug retatrutide was associated with significant improvement in knee <a href=\"https:\/\/emedicine.medscape.com\/article\/330487-overview\">osteoarthritis<\/a> (OA) pain and physical function along with weight loss in people with painful knee osteoarthritis and <a href=\"https:\/\/emedicine.medscape.com\/article\/123702-overview\">obesity<\/a>, data from two phase 3 trials showed.<\/p>\n<p>\u201cWe saw very exciting amounts of pain reduction and function improvement over time. I think this is a big advance\u2026 Osteoarthritis has lacked effective therapies for so long,\u201d study investigator Philip Conaghan, MBBS, PhD, director of the NIHR Biomedical Research Centre in Leeds and professor of musculoskeletal medicine at the University of Leeds, United Kingdom, told <em>Medscape Medical News<\/em>.<\/p>\n<p>The data came from Eli Lilly\u2019s TRIUMPH-4 trial, of once-weekly retatrutide in different doses compared with placebo for 68 weeks, and TRIUMPH-1-OA, a substudy of a larger trial investigating the triple GLP-1, GIP, and <a href=\"https:\/\/reference.medscape.com\/drug\/gvoke-glucagen-glucagon-342712\">glucagon<\/a> receptor agonist for treating obesity. Conaghan presented results from TRIUMPH-4 on November 8, 2026, and will present the TRIUMPH-1-OA data on November 10, 2026, both at the <a href=\"https:\/\/www.medscape.com\/c25\/p14\/american-college-rheumatology-acr-2026-annual-meeting-2026a100128n\">American College of Rheumatology (ACR) 2026 Annual Meeting<\/a> in Orlando, Florida.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The investigational triple incretin agonist drug retatrutide was associated with significant improvement in knee osteoarthritis (OA) pain and physical function along with weight loss in people with painful knee osteoarthritis and obesity, data from two phase 3 trials showed. \u201cWe saw very exciting amounts of pain reduction and function improvement over time. I think this [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-246974","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/246974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=246974"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/246974\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=246974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=246974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=246974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}